-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Sharing Best Practices from the ALL/LBL Clinic: Navigating Patient-Centered Care with Asparaginase Therapies

Sponsor: Jazz Pharmaceuticals, Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Education, Diseases, Treatment Considerations, Adverse Events
Friday, December 6, 2024: 3:00 PM-6:00 PM
Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)
Chair:
Ibrahim Aldoss, MD, City of Hope Duarte Cancer Center
Disclosures:
Aldoss: AbbVie: Other: research support; Takeda Pharmaceuticals: Other: consulting fees; Kite Pharma: Other: consulting fees; Sobi: Other: consulting fees; Jazz Pharmaceuticals: Other: consulting fees; Pfizer: Honoraria, Other: consulting fees; Syndax Pharmaceuticals, Inc.: Other: consulting fees; Amgen: Honoraria, Other: consulting fees.
Speakers:
Cate O'Reilly, MSW, Patient and Caregiver Advocate, Cancer Support Community , Luke Maese, DO, University of Utah, Huntsman Cancer Institute, Primary Children’s Hospital and Sandra Kurtin, PhD, ANP-BC, AOCN, FAPO, Clinical Assistant Professor of Medicine
Disclosures:
Maese: Jazz pharmaceuticals: Consultancy, Speakers Bureau; Servier: Membership on an entity's Board of Directors or advisory committees.

On Demand program will be available here December 21, 2024.

Access Program Here

On Demand program will be available here December 21, 2024.

This 90-minute patient-centric symposium will explore navigating the patient journey with asparaginase therapies as part of the treatment strategy for acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). The lively and engaging format will feature a series of video-based clinical vignettes, each modeling best practices in patient-clinician communication, contextualized within a review of the essential role of currently available asparaginase therapies in the optimal management of ALL/LBL. Faculty commentary and expert guidance will focus on how to select therapy, assess treatment efficacy, and recognize and manage the wide range of potential toxicities associated with asparaginase treatment. The expert faculty panel will include an adult hematologist/oncologist, a pediatric hematologist/oncologist, a hematologic oncology nurse specialist, and a patient advocate.

See more of: Friday Satellite Symposia
<< Previous Application | Next Application >>